Lupin (500257) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 saw strong double-digit growth in revenues and margins, with consolidated sales reaching ₹56,003.3 million, up 16% YoY, and EBITDA margin at 23.3%, driven by new product launches, operational improvements, and lower R&D spend.

• Net income surged 77% YoY to ₹8,013.1 million, with margin at 14.5%.

• All key geographies delivered robust sales and profitability, with North America up 28% YoY, India up 18% YoY, and EMEA up 26% YoY.

• Quality and compliance improved, with positive inspection outcomes at multiple facilities.

• Continued focus on complex generics, biosimilars, and operational efficiency.

Financial highlights

• Q1 FY25 sales reached ₹56,003.3 million, up 16% YoY; EBITDA was ₹12,864 million, up 50% YoY; net income was ₹8,013.1 million, up 77% YoY.

• US sales were $227 million, up 25% YoY and 8% QoQ (constant currency).

• Gross margin improved to 68.4% from 65.4% YoY and 67.8% in Q4.

• EBITDA (ex-forex/other income) margin at 23.3% vs 20.4% in Q4.

• Employee expenses rose 15% YoY to ₹971 crore; manufacturing expenses at ₹1,598 crore, up 8.6%.

Outlook and guidance

• US business expected to grow high single-digit in FY25, with further ramp-up from new launches.

• Poised to launch ~20 new products in India in FY25, with a strong pipeline in complex generics and biosimilars.

• R&D spend projected at ₹1,800 crore for FY25, with focus on complex generics, respiratory, and injectables.

• Confident of maintaining gross margins around current levels barring unforeseen events.

• Strategic growth drivers and new product pipeline expected to sustain top-line and EBITDA growth beyond FY25.